Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...
Officials with Trinity Health are grateful for the support of the community, including donations toward a $5 million goal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback